$$$ Targeted Genetics Corp.$$$ Blockbuster for Future - 500 Beiträge pro Seite

[paloma]

TGEN ist die letzten Monate ziemlich ins aus den Fokus geraten. Die positiven Meldungen der letzten beiden Tage enthalten viel ermutigende Tatbestände und beweisen das Blockbuster-Potential erneut. Lest selbst.




News vom 08.11.2006

Targeted Genetics Reports Third Quarter 2006 Financial Results
SEATTLE, WA, Nov 08, 2006 (MARKET WIRE via COMTEX News Network) -- Targeted Genetics Corporation (NASDAQ: TGEN) reported financial results today for the quarter ended September 30, 2006. As previously announced, the Company will hold a conference call with analysts at 10:30 AM Eastern Time today. The call will be broadcast live over the Internet and can be accessed, along with replay information, at www.targetedgenetics.com.

Targeted Genetics reported a net loss of $3.2 million, or $0.32 per share in the third quarter of 2006, compared to a net loss of $5.7 million, or $0.66 per share, for the same period in 2005.

Revenue for the three months ended September 30, 2006 was $2.0 million, compared to $1.5 million for the third quarter of 2005, and was $5.9 million for the nine months ended September 30, 2006, compared to $4.9 million for the same period in 2005. Revenue in 2006 consists primarily of development revenue earned under a congestive heart failure collaboration agreement with Celladon and an HIV/AIDS vaccine collaboration with the International AIDS Vaccine Initiative (IAVI). Revenue in 2006 also includes development revenue from an NIAID contract to develop AAV-based HIV/AIDS vaccines. Revenue in 2005 primarily consisted of development revenue earned under the IAVI collaboration.

Total operating expenses for the quarter ended September 30, 2006 decreased to $5.2 million from $7.3 million for the third quarter of 2005. Operating expenses for the nine months ended September 30, 2006 increased to $40.8 million, compared to $20.6 million for the same period in 2005. Results for 2006 include a non-cash goodwill impairment charge of $23.7 million recorded in the second quarter. Please refer to the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2006 for more detailed information about the goodwill impairment charge.

Research and development expenses in the third quarter of 2006 decreased to $3.1 million, compared to $4.7 million for the same period in 2005. Research and development costs for the nine months ending September 30, 2006 decreased to $10.5 million from $14.0 million for the same period in 2005. These decreases reflect the Company's focus on advancing its lead Arthritis product candidate and executing on its funded product development activities.

General and administrative expenses in the third quarter of 2006 increased slightly to $1.7 million from $1.5 million for the same period in 2005. This increase in G&A expense is primarily due to the recognition of stock based compensation expense in 2006 as a result of the implementation of Financial Accounting Standard No. 123 (R) "Share Based Payment." General and administrative expense decreased to $4.7 million for the nine months ended September 30, 2006, from $5.0 million for the same period in 2005. The decrease in G&A expense is due primarily due to lower patent costs and lower payroll expense, and is partially offset by the recognition of stock based compensation expense in 2006.

Restructuring charges for the three months ended September 30, 2006 decreased to $413,000 compared to $1.2 million for the three months ended September 30, 2005. Restructuring charges for the third quarter of 2006 include a charge to revise the time it will take to secure a sublease tenant for the Company's leased facility in Bothell, Washington.

"We've had a good quarter and are finishing the year with a lot of momentum. Yesterday we announced that we restructured our debt with Biogen Idec, bolstering our financial position essential for advancing our clinical programs and engaging in strategic partnerships," said H. Stewart Parker, President and Chief Executive Officer. "In our lead clinical program in inflammatory arthritis, we are scheduled to report additional interim Phase I/II tgAAC94 data on the safety and effects on signs and symptoms of arthritis in the first 60 subjects at the American College of Rheumatology Meeting next week, and we have already begun enrollment of the second half of the study. Also during the third quarter, we were issued important patents that, broaden our classes of potential therapeutic targets. In addition, we reported positive Phase I data from our HIV/AIDS vaccine development program, demonstrating the potential for immune response to vaccine antigens at higher doses. We are achieving the goals we set out to meet and have taken a number of significant steps to afford us the resources needed to advance our clinical programs and to execute on our strategic initiatives in 2007."

Third quarter and recent highlights include:


Restructured debt owed to Biogen Idec, converting $5.65 million of debt into 1 million common shares. The remaining $2.5 million debt owed to BIIB will be repaid on a new time table;
Strengthened the Company's leadership in developing adeno-associated virus (AAV) based therapies through the issuance of two additional patents, the first covering AAV expressed RNAi, and the second covering AAV1 serotypes and pseudotypes, highly efficient for gene expression in muscle and other slowly dividing cells;
Made significant advances in the development, purification, and manufacture of AAV1 vectors at commercial scale;
Reported encouraging interim Phase I HIV/AIDS Vaccine data; the vaccine candidate is well tolerated and an immune response was observed in a subset of patients; and
Completed enrollment of the first 60 subjects and opened enrollment to the second half of the Phase I/II investigational study for tgAAC94 in patients with inflammatory arthritis.

As of September 30, 2006, the Company had $9.3 million in cash and cash equivalents, as compared to $14.1 million at December 31, 2005. "We started the year with about $14 million in cash. During 2006, we raised $4.8 million net proceeds from the sale of common shares and used $9.5 million to fund operations, net of funding from our partnered programs," said David J. Poston, Vice President, Finance, and Chief Financial Officer. "Given our careful use of cash and balance of resources, we are on track to meet our full-year 2006 operating forecast in the range of $13 to $16 million."

Conference Call and Webcast Information

The company will host a conference call reviewing financial results and its product portfolio, including an update on the development progress of the Company's inflammatory arthritis and other clinical and business developments, today beginning at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time. You may access the live webcast via the "Events" section of the Company's website at www.targetedgenetics.com or via telephone at 866-249-5225 (domestic) or 303-262-2211 (international).

Replay Access

Webcast replay will be available for approximately 90 days at www.targetedgenetics.com ; telephone replay will be available following today's call at 9:30 a.m. PT through 11:59 p.m. PT, Friday, December 8, 2006, by calling 800-405-2236 (domestic) or 303-590-3000 (international); passcode 11074555#.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis and other acquired and inherited diseases with significant unmet medical need. The Company uses its considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. The Company's product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure, Huntington's disease and hyperlipidemia. To learn more about Targeted Genetics, visit the Company's website at www.targetedgenetics.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding the Company's business strategy, the Company's product development, the Company's liquidity and the Company's ability to meet the Company's ongoing financial obligations and other statements about the Company's plans, objectives, intentions and expectations. These unaudited results announced herein may differ from what the Company eventually files in its Annual Report on Form 10-K for the fiscal year ended December 31, 2006. In particular, the statements regarding the Company's future plans are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect the Company's actual results include, but are not limited to, the Company's ability to raise capital when needed, the timing, nature and results of the Company's clinical trials, potential development of alternative technologies or more effective products by competitors, the Company's ability to obtain and maintain regulatory or institutional approvals, the Company's ability to maintain its listing on the NASDAQ Capital Market and the Company's ability to obtain, maintain and protect the Company's intellectual property, as well as other risk factors described in "Item 1A. Risk Factors" in our most recent report on Form 10-K or Form 10-Q that we file with the SEC. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change the Company's expectations.

TARGETED GENETICS CORPORATION
(in thousands, except per share information)
Quarter ended Year-to-date ended
Statement of Operations September 30, September 30,
Information: 2006 2005 2006 2005
----------- ----------- ----------- -----------
(unaudited) (unaudited) (unaudited) (unaudited)
Revenue:
Collaborative
agreements $ 2,012 $ 1,468 $ 5,856 $ 4,930
----------- ----------- ----------- -----------
Total revenue 2,012 1,468 5,856 4,930
Operating expenses:
Research &
development 3,123 4,653 10,483 14,000
General &
administrative 1,687 1,490 4,736 5,035
Restructure charges 413 1,188 1,818 1,526
Goodwill impairment
charge - - 23,723 -
----------- ----------- ----------- -----------
Total expenses 5,223 7,331 40,760 20,561
----------- ----------- ----------- -----------
Loss from operations (3,211) (5,863) (34,904) (15,631)
Investment income 147 315 468 382
Interest expense (126) (135) (362) (400)
----------- ----------- ----------- -----------
Net loss $ (3,190) $ (5,683) $ (34,798) $ (15,649)
=========== =========== =========== ==========
Net loss per common
share $ (0.32) $ (0.66) $ (3.64) $ (1.83)
=========== =========== =========== ==========
Shares used in
computation of net
loss per common share 9,894 8,563 9,548 8,563
=========== =========== =========== ===========
TARGETED GENETICS CORPORATION
(in thousands)
September 30, December 31,
Balance Sheet Information: 2006 2005
------------ ------------
(unaudited)
Cash and cash equivalents $ 9,280 $ 14,122
Other current assets 1,248 1,063
Property and equipment, net 1,282 1,747
Other assets 8,135 31,866
------------ ------------
Total assets $ 19,945 $ 48,798
============ ============
Current liabilities $ 6,568 $ 4,628
Long-term obligations and other liabilities 11,893 13,599
Shareholders' equity 1,484 30,571
------------ ------------
Total liabilities and shareholders' equity $ 19,945 $ 48,798
============ ============


Investor and Media Contact:
Stacie D. Byars
Director, Communications
Targeted Genetics Corporation
[phone]

SOURCE: Targeted Genetics


News vom 07.11.2006

Targeted Genetics and Biogen Idec Restructure Debt
SEATTLE, WA, Nov 07, 2006 (MARKET WIRE via COMTEX News Network) -- Targeted Genetics Corporation (NASDAQ: TGEN) announced that it has entered into a newly amended agreement with Biogen Idec, Inc. (NASDAQ: BIIB) to restructure repayment of $8.15 million of debt. Under the terms of this amendment, Biogen Idec has agreed to convert $5.65 million of debt into 1 million shares of Targeted Genetics common stock. Targeted Genetics will pay $500,000 of the remaining debt immediately and the remaining $2 million in debt will be paid according to a new repayment schedule.

As a result of the restructured relationship, Biogen Idec's equity holdings in Targeted Genetics will increase to 19.9% of the total outstanding common stock.

"We are extremely pleased to have successfully modified the debt arrangement with Biogen Idec. The successful renegotiation of this debt with Biogen Idec reduces our long-term cash needs and strengthens the company financially," said H. Stewart Parker, President and Chief Executive Officer. "As a result, we are able to work toward accomplishing additional measures to leverage value from our capabilities to build additional financial resources."

Under this amended agreement, Targeted Genetics has agreed to make payments of $1 million in August 2007 and $1 million in August 2008. Such payments are subject to acceleration in the event of receipt of certain milestone payments from third parties or certain key events. The Funding Agreement between Targeted Genetics and Biogen Idec originated in August 2000 and was first restructured in September 2005.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative, targeted molecular therapies for the prevention and treatment of inflammatory arthritis, HIV/AIDS and other acquired and inherited diseases with significant unmet medical need. Targeted Genetics uses its considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Its product development efforts target inflammatory arthritis, HIV/AIDS, congestive heart failure, Huntington's disease, and hyperlipidemia. To learn more about Targeted Genetics, visit its website at www.targetedgenetics.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding our debt restructuring with Biogen Idec, our cash horizon and financial needs, our ability to raise capital and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, our ability to raise capital when needed, our ability remain compliant with the Nasdaq Capital Market continued listing requirements, our ability to obtain, maintain and protect our intellectual property, the timing, nature and results of research and clinical trials, potential development of alternative technologies or more effective processes by competitors, and, our ability to obtain and maintain regulatory or institutional approvals, as well as other risk factors described in Item 1A. Risk Factors in our report on Form 10-K for the year ended December 31, 2005 and updated in Item 1A. Risk Factors in our Form 10-Q for the quarter ended June 30, 2006. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

Investor and Media Contact:
Stacie D. Byars
Director, Communications
Targeted Genetics Corporation
[phone]

SOURCE: Targeted Genetics Corporation

[paloma]

Schöne fette Käufe die letzten Tage.

Volumen seit Gestern erstaunlich.

[paloma]

Wohin treibt der Kurs? Kleinste Schwächen werden prompt mit fetten Käufen beantwortet.

[URANI]

Antwort auf Beitrag Nr.: 25.244.192 von paloma am 09.11.06 18:05:51

Das wird was......

[paloma]

Lecker

[paloma]

Das mir keiner sagt, es hat ja keiner drauf hingewiesen.

[paloma]

freue ich mich halt alleine.

[paloma]

Schön und beständig aufwärts. Hürde 4 $ wird vorbildlich genommen. Macht Mut auf mehr.

Entschuldigung, rede nur mit mir selbst.

[paloma]

HOW on Friday!

[paloma]

Gibt`s Morgen noch mal ein Shortie-Grill-Party?


Entsprechend Short-Interest-List Day to Cover 1.17

[paloma]

Erneut News von TGEN

Evidence of Safety at All Dose Levels and Trend in Sustained Decrease in Signs and Symptoms of Disease in Target Joint

Targeted Genetics Corporation (NASDAQ: TGEN) announced that the principal investigator for its current clinical studies, Philip J. Mease, M.D., Chief, Rheumatology Clinical Research Division of Swedish Hospital Medical Center and Head of Seattle Rheumatology Associates, will present additional interim data today from the ongoing Phase I/II trial of tgAAC94 in patients with inflammatory arthritis. Dr. Mease will present these data in a poster presentation, titled "A Phase 1/2 Clinical Study of Intra-articular Administration of a Recombinant Adeno-Associated Vector Containing a TNF-alpha Antagonist Gene in Inflammatory Arthritis," at the American College of Rheumatology meeting, taking place in Washington, D.C.

The data continue to support the safety and tolerability of intra-articular administration of tgAAC94 to affected joints in doses up to 1x10(13) DRP/mL of joint fluid and suggest that tgAAC94 may lead to decrease in signs and symptoms of arthritis in injected joints. Importantly, these decreases in injected joint tenderness and swelling were observed in inflammatory arthritis subjects with or without concurrent systemic TNF-alpha antagonist therapies.

"Many patients with inflammatory arthritis fail to achieve sufficient disease control in one or more joints and continue to experience pain and discomfort. The goal with targeted localized therapy is to increase the amount and duration of TNF inhibition in the problem joint to improve response and decrease the possibility that the inflammation will lead to destruction of individual joints," said Dr. Mease. "The safety and responses observed in clinical trials to date suggest that tgAAC94 has the potential to advance the care of patients with inflammatory arthritis. If tgAAC94 proves to be safe and efficacious, I can envision individualizing treatment of patients with the combination of systemic therapy and local therapy that works best for the patient."

tgAAC94 is an investigational therapeutic designed to inhibit the activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. tgAAC94 utilizes an adeno-associated virus (AAV) vector to deliver the gene encoding a soluble form of the receptor for TNF-alpha (TNFR: Fc) directly to affected joints. TNFR:Fc protein is a potent inhibitor of TNF-alpha.

In the ongoing Phase I/II study, approximately 120 adults are being randomized into three dose levels to receive a single intra-articular injection of either tgAAC94 or placebo, followed by an open-label injection of tgAAC94 after 12 to 30 weeks, depending on when swelling in the target joint meets criteria for re-injection. As of October 2006, 61 subjects in the first three cohorts, 34 of whom were receiving concurrent TNF-alpha antagonists, received an injection of blinded study drug into the knee (n=30), ankle (n=10), wrist (n=11), metacarpophalangeal joint (n=6) or elbow (n=4). These patients were predominantly rheumatoid arthritis patients, although a small number of psoriatic arthritis and ankylosing spondilitis patients have participated. The data suggest that:

-- no significant safety concerns have been identified after 4 to 60
weeks of follow-up;

-- fewer subjects receiving tgAAC94 had symptoms requiring re-injection
prior to the 30-week time point, compared with subjects in the placebo arm;

-- the time to second injection in subjects randomized to receive tgAAC94
was longer than those who were randomized to placebo;

-- a trend toward improvement in tenderness and swelling of injected
joint in subjects receiving tgAAC94 was observed; and

-- these improvements were noted in subjects taking concurrent systemic
TNF-alpha antagonist therapy as well as those subjects who were not on
these therapies.

Based on the favorable safety profile of the first three dose-escalation cohorts, the Data Monitoring Committee overseeing the study has given permission for remaining 60 subjects to be enrolled at the same three dose levels to increase the power of the study.

H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics, added, "We are encouraged by the continued positive trends in this additional data and pleased to have the opportunity to share the results of our tgAAC94 clinical studies with members of the medical community. We believe that our unique approach for localized delivery of a protein therapeutic holds the promise of more comprehensive treatment for patients suffering with inflammatory arthritis."

About tgAAC94

tgAAC94 is being developed as a potential supplement to systemic anti-TNF-alpha protein therapy for use in patients with inflammatory arthritis who have one or more joints that do not fully respond to systemic protein therapy. The product candidate uses Targeted Genetics' recombinant AAV (rAAV) vector technology to deliver a DNA sequence that encodes a soluble form of the TNF-alpha receptor (TNFR: Fc). Soluble TNFR:Fc inhibits the immune stimulating activity of TNF-alpha. Direct injection of tgAAC94 into affected joints leads to the localized production of secreted TNFR:Fc within joint cells, reducing the activity of TNF-alpha within the joint and, potentially, leading to a decrease in the signs and symptoms of inflammatory disease and inhibition of joint destruction. The Company's rAAV technology platform is used to deliver genes and is based on AAV, a naturally occurring virus that has not been associated with any disease in humans.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative, targeted molecular therapies for the prevention and treatment of inflammatory arthritis, HIV/AIDS and other acquired and inherited diseases with significant unmet medical need. Targeted Genetics uses its considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Its product development efforts target inflammatory arthritis, HIV/AIDS, congestive heart failure, Huntington's disease, and hyperlipidemia. To learn more about Targeted Genetics, visit its website at www.targetedgenetics.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding the data to be collected in this trial, the establishment or determination of efficacy endpoints from the data collected in the trial, the timely and complete accrual of subjects in the trial and our ability to commercialize tgAAC94 and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, our ability to obtain, maintain and protect our intellectual property, our ability to raise capital when needed, our ability to recruit and enroll suitable trial participants, the timing, nature and results of research and clinical trials, potential development of alternative technologies or more effective processes by competitors, and, our ability to obtain and maintain regulatory or institutional approvals, as well as other risk factors described in Item 1A. Risk Factors in our report on Form 10-K for the year ended December 31, 2005 and updated in Item 1A. Risk Factors in our Form 10-Q for the quarter ended March 31, 2006. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.



Source: Market Wire (November 13, 2006 - 8:00 AM EST)

News by QuoteMedia
www.quotemedia.com

[paloma]

Im Auge behalten.

[paloma]

[URANI]

Jetzt wird geerntet...............

[paloma]

Antwort auf Beitrag Nr.: 25.746.456 von URANI am 27.11.06 15:54:12

Mit der Ernte würde ich noch warten, meine Meinung. Die 5 $ sind schnell überschritten.

[URANI]

Antwort auf Beitrag Nr.: 25.746.533 von paloma am 27.11.06 15:58:04

Wollte gerade sagen...ich will die 5 US$ sehen.....

[URANI]

Antwort auf Beitrag Nr.: 25.746.641 von URANI am 27.11.06 16:02:47

[paloma]

Antwort auf Beitrag Nr.: 25.746.641 von URANI am 27.11.06 16:02:47

... und dies war erst der Anfang.

[paloma]

Da ist was im Busch. Suche nach News


Nichts zu finden. Bin mir sicher, da wissen einige mehr.

[paloma]

Nächste Hürde: 6 $[imghttp://smileys.sur-la-toile.com/repository/Surpris/3d-surpris-non.gif][/img]

[paloma]

Volumen bereits bei 1.4 MIO Shares.

[paloma]

6 $ durchstossen

Soeben 2 Riesenorders a` 150K.

Wer möchte noch mitfliegen und sich nicht in den Boden bohren (wie bei vielen Explorern üblich)? Hier ist was im Busch. Dieser Handel ist nicht das übliche Quantum. Bereit 2.1 MIO Shares - und dies ohne News.

[BarnyXXL]

Im Yahoo-Board wird u.a. BIOGEN dahinter vermutet. Vielleicht eine Übernahme ?

[paloma]

Hört sich phänomenal an. Sollte sich dies bewahrheiten, gibt`s einen gewaltigen Squeeze-Out.

Umsatz mittlerweile 3.7 MIO Shares

[BarnyXXL]

Oder es könnte mit tgAAC94 zusammenhängen; ein Arthritis-Mittel in der klinischen Phase.

[paloma]

Antwort auf Beitrag Nr.: 25.750.794 von BarnyXXL am 27.11.06 18:52:44

What`s the matter?

Hab natürlich auch schon drüber spekuliert. Beides ist TGEN dienlich. Fakt bleibt, hier geschieht extremes ... und dies noch ohne NEWS. Wir sind dabei. Dann werden wir uns erst mal beim
vergnügen.

[URANI]

Antwort auf Beitrag Nr.: 25.751.126 von paloma am 27.11.06 19:01:31

Wie gut das ich vorhin auf dich gehört habe!! Habe noch keine einzige Aktie verkauft.....

[URANI]

Antwort auf Beitrag Nr.: 25.752.859 von URANI am 27.11.06 19:49:08

Werde aber einen kleinen Teil noch heute verkaufen so um die 6,50 - 7 US$.

[paloma]

Antwort auf Beitrag Nr.: 25.752.971 von URANI am 27.11.06 19:51:45

Kann ich nachvollziehen. Wie ich TGEN kenne, gib`s die letzte Handelsstunde noch mal einen kräftigen Schub - nach oben.

Hat sich bei Dir ja schön rentiert - sofern Du meinem ursprünglichen Empfehlung (Push :rolleyes ernst genommen hast.

Würde aber auch nur einen Teil verkaufen.

PS: ich bleib drin. Volumen lügt nicht.

[URANI]

Antwort auf Beitrag Nr.: 25.753.119 von paloma am 27.11.06 19:56:19

Jep, hat sich sehr gelohnt. Bin am gleichen Tag noch mit einer kleinen Stückzahl rein. Und 1 Woche später habe ich dann nochmal kräftig zugeschlagen. Komplett gehe ich auch nicht raus. Aber ein paar Gewinne mitzunehmen ist ja auch nicht verkehrt. Der Einsatz ist raus und die Gweinne laufen weiter

[paloma]

Antwort auf Beitrag Nr.: 25.753.631 von URANI am 27.11.06 20:19:13

You are the

Gruß

[URANI]

Antwort auf Beitrag Nr.: 25.753.775 von paloma am 27.11.06 20:27:38

[paloma]

Antwort auf Beitrag Nr.: 25.753.775 von paloma am 27.11.06 20:27:38

... und ich der glückliche Bagholder

[BarnyXXL]

bizjournals.com
Targeted Genetics' stock skyrockets 52 percent
Monday November 27, 4:36 pm ET


Shares in Targeted Genetics Corp. shot up more than 52 percent in trading Monday, but company officials say they don't know why the stock price skyrocketed.
"We don't have any announcements, and I don't have any rumors," said Stacie Byars, director of communications for the Seattle biotech.

She did point out that earlier this month Targeted Genetics reduced its debt to Biogen Idec, as the Massachusetts company took a larger ownership stake in the Seattle biotech (NASDAQ: TGEN - News).

In May, Targeted Genetics enacted a one-for-10 reverse stock split, which raised the company's stock price from the 35-cent-per-share range to more than $3 per share. In Monday trading, shares in Targeted Genetics shot up $2.03 to close at $5.87.

Published November 27, 2006 by the Puget Sound Business Journal

[paloma]

Antwort auf Beitrag Nr.: 25.763.833 von BarnyXXL am 28.11.06 09:07:21

Guten Morgen BarnySL

Es wird gemunkelt, daß BIOGEN den ganzen Laden übernehmen möchte. Bereits am 07.11. wurden 1 MIO Shares am Markt erworben.

[URANI]

Antwort auf Beitrag Nr.: 25.764.018 von paloma am 28.11.06 09:19:35

[URANI]

Time Ex Price Change Volume

08:52:43 Q 5.77 -0.10 290

08:52:43 Q 5.77 -0.10 300

08:52:43 Q 5.77 -0.10 200

08:52:43 Q 5.76 -0.11 500

08:32:40 Q 5.77 -0.10 800

08:32:40 Q 5.77 -0.10 200

08:24:58 Q 5.77 -0.10 800

08:24:58 Q 5.77 -0.10 200

08:23:12 Q 5.77 -0.10 300

08:23:12 Q 5.77 -0.10 200

[paloma]

Hallo Investoren (ihr wenigen Glücklichen)

Wie ist die allgemeine Erwartungshaltung?

Die gestrige Konsolidierung auf hohem Niveau scheint auszupendeln. Vorbörslich gehts zumindest schon mal wieder aufwärts.

Gruß

[paloma]

Vermutung scheint sich doch zu bestätigen.
Erholungspotential bis 15 $ ist drin.

[paloma]

Trifft so ziemlich meine Vorstellungen. Kursziel TGEN bei Bestätigung der Gerüchte (Übernahme seitens BIOGEN)

Posting eines Users im Yahoo-Board
you will see 200% return when they make annonocement.

[paloma]

Hier noch ein Langfrist-Chart. Da sieht der bisherige Upmove nur nach Donnerrollen aus.

[URANI]

Keiner mehr hier.........

[URANI]

Antwort auf Beitrag Nr.: 25.838.180 von URANI am 30.11.06 21:09:52

ziiieeeeeehhhhhhhhhhhhhhhhhhhh................

[URANI]

Erste Position zu 6,90 US$ verjauft....

[URANI]

Antwort auf Beitrag Nr.: 26.027.822 von URANI am 08.12.06 17:16:32

Zweite Posi zu 7 US $ verkauft... Den Rest lass ich erstmal laufen.... Danke an den Thread eröffner vor x-Tagen. ohne dich hätte ich nicht ordentlich abgesahnt

[URANI]

Targeted Genetics Leverages Value of Its AAV Patent Estate in Licensing Agreement With Amsterdam Molecular Therapeutics


2006-12-12 07:30 ET - News Release

SEATTLE, WA -- (MARKET WIRE) -- 12/12/06


Targeted Genetics Corporation (NASDAQ: TGEN) today announced that the company has licensed two patents in its broad portfolio of AAV intellectual property to Amsterdam Molecular Therapeutics B.V. (AMT). The non-exclusive license to U.S. patents #6,759,237 and #7,105,345, which were issued to the University of Pennsylvania and exclusively licensed to Targeted Genetics, provides AMT with the rights to use AAV1 in the development and commercialization of therapeutic products for treating type I and type V lipoprotein lipase (LPL) deficiencies. AMT currently is conducting Phase II trials of AMT-011, an AAV1-based therapy for type I LPL deficiency, and anticipates launching the product in the European Union in 2008. LPL deficiency in humans is a severe and debilitating disease associated with extremely high serum triglyceride concentrations, high morbidity, and increased mortality.

Under the terms of the non-exclusive license, Targeted Genetics will receive an upfront payment from AMT of $1,750,000, as well as milestone payments and royalties on the sale of any products commercialized using the licensed technology.

"This agreement demonstrates our ability to leverage our portfolio of AAV-related intellectual property assets to generate revenue for Targeted Genetics and value for our shareholders," said H. Stewart Parker, president and chief executive officer of Targeted Genetics. "In addition, it allows us to participate, financially, in the commercialization of AAV therapeutics by others. We are truly seeing the expansion of interest in AAV-based molecular medicines as a therapeutic platform. AMT-011 could be the first commercially available AAV-based therapeutic and may provide us with relatively near-term milestones and potential royalty revenue streams to support our internal product development efforts. We wish AMT success as they move this therapeutic candidate through development."

AMT-011 uses a recombinant AAV1 vector to deliver the gene encoding lipoprotein lipase. In preclinical studies, AMT-011 has demonstrated effective replacement of LPL gene function, leading to complete normalization of triglyceride levels in two different LPL deficient animal models. A pivotal trial of AMT-011 in patients with type I LPL deficiency was initiated in December 2005 and is ongoing.

"This license is a key step in AMT's commercialization strategy of its lead drug candidate AMT-011. This breakthrough gene therapy may allow AMT to provide patients suffering from a serious, debilitating and often life-threatening metabolic disease, caused by a monogenetic defect, a fundamental cure," said Ronald H.W. Lorijn, M.D., Ph.D., M.B.A., Chief Executive Officer of AMT.

About LPL Deficiency

LPL deficiency is caused by a deficiency or loss of LPL, the principal enzyme involved in the clearance of triglycerides from the bloodstream. Affected patients develop chronic pancreatitis, ultimately resulting in diabetes mellitus. The dysregulation in lipid metabolism that occurs in LPL deficiency also predisposes affected patients to cardiovascular diseases, including coronary artery disease and heart attack. Currently, the only effective treatment for the condition is a severe reduction in the consumption of dietary fat, a regimen to which many patients have difficulty adhering. AMT estimates the worldwide population of LPL type I deficiency at 4,000 patients and LPL type V deficiency at approximately 100,000.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development of innovative targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. Targeted Genetics' proprietary Adeno-Associated Virus (AAV) technology platform allows it to deliver genes coding proteins to increase gene function, as well as RNAi to decrease or silence gene function. Targeted Genetics' product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure and Huntington's disease. To learn more about Targeted Genetics, visit the Company's website at www.targetedgenetics.com.

About AMT

Amsterdam Molecular Therapeutics BV is a fully integrated gene therapy company founded by scientists of the University of Amsterdam Medical Center (AMC) in 1998. AMT focuses on the development of gene-based therapies for orphan metabolic, central nervous system and ocular diseases. AMT's long-term gene expression technology is based on specific delivery of therapeutic genes into target organs or tissues. Its lead product, AMT-011, is in phase II for the first indication: treatment of lipoprotein lipase deficiency type I. For further information, visit AMT's website at www.amtbv.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding our licensee's ability to develop, manufacture, accurately interpret clinical results, obtain regulatory approvals and commercialize any therapeutic products covered under the license agreement, the market prospects for any therapeutic products covered under the license agreement, our benefits, including milestone and royalty payments, that we expect to derive as a result of this license, and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, our ability to obtain, maintain and protect our intellectual property, our ability to raise capital when needed, our licensee's ability to recruit and enroll suitable trial participants, the timing, nature and results of research and clinical trials of our license, potential developments of alternative technologies or more effective processes by parties other than the licensee, and, our licensee's ability to obtain and maintain regulatory or institutional approvals, as well as other risk factors described in "Part I, Item 1A. Risk Factors" in our most recent annual report on Form 10-K or "Part II, Item 1A. Risk Factors" in our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.


Investor and Media Contact:
Stacie D. Byars
Director, Communications
Targeted Genetics Corporation
[phone]

[MaatMod]

Freigabe für aktuelle Diskussion.

MfG MaatMOD

[GoldenStock]

Hey.
Hat noch jemand TGEN auf der Watchlist ???

Beobachte schon seit gut 2 Jahren , zwischen durch mal auf 7 $
nun mal kurz bei 0,50 $.

Was meint ihr evtl. ein günstiger Einstieg ??

GoldenStock

[GoldenStock]

Nun schon bei 0,20 Euro.

Denk ich werd mir jetzt mal ein paar Tausend Stücke holen.

Hoff ich werd diese dann in 1-2 Jahren steuerfrei, wieder
so um 1-2-3 Euro los.......

GoldenStock